3.960SEK-22.96%Mkt Cap: 519.88M SEKP/E: —Last update: 2026-06-11
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involv…
Industry Peers
Biotechnology110.59BUSDP/E 25.9
99.24BDKKP/E 19.1
63.08BUSDP/E 14.7
51.59BEURP/E 33.7
48.23BEURP/E 39.7
38.88BUSDP/E 73.0
31.39BUSDP/E 28.7
31.33BSEKP/E 46.4
Indicators:|
Key Statistics
Company
Market Cap519.88M SEK
Enterprise Value128.48M SEK
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-47.65M SEK
Revenue/Share—
Last Price3.960 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees10
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-42.83
PEG—
EV/EBITDA-2.20
EV/Revenue—
P/S—
P/B52.45
EPS (TTM)-0.55
EPS (Forward)-0.12
52W Range
1.30051% of range6.500
52W High6.500 SEK
52W Low1.300 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-144.75%
ROA-80.71%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-34.59M SEK
CapEx (TTM)—
FCF Margin—
FCF Yield-3.43%
Net Debt-30.68M SEK
Net Debt/EBITDA0.53
Balance Sheet
Debt/Equity0.08
Current Ratio1.36
Quick Ratio1.30
Book Value/Sh0.0980 SEK
Cash/Share0.2870 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)5.000 SEK
Target Range5.000 SEK – 5.000 SEK
# Analysts1
Ownership
Shares Out.114.91M
Float69.17M
Insiders42.95%
Institutions9.07%
Technical
SMA 501.443 (+174.4%)
SMA 2002.018 (+96.3%)
Beta-0.07
S&P 52W Chg22.64%
Avg Vol (30d)832.41K
Avg Vol (10d)153.73K
Technical Indicators
RSI (14)95.4
MACD0.4888
MACD Signal0.1170
MACD Hist.+0.3718
BB Upper3.953 SEK
BB Middle1.740 SEK
BB Lower-0.4735 SEK
BB Width254.45%
ATR (14)0.5071 SEK
Vol Ratio (20d)5.68x